Three European Retrospective Real-World Chart Review Studies to Determine the Effectiveness of Flash Glucose Monitoring on HbA1c in Adults with Type 2 Diabetes
Authors:
Open Access
- 12 December 2019
- journal article
- review article
- Published by Springer Nature in Diabetes Therapy
- Vol. 11 (1) , 279-291
Abstract
Introduction The impact of flash glucose monitoring technology on HbA1c in type 2 diabetes managed by basal bolus insulin is uncertain. Three parallel European retrospective non-interventional chart review studies collected data reported in medical records. Each country’s study aim was to determine the effectiveness of the device on HbA1c when used by their population for 3–6 months as their standard of care for management of glycaemia in a real-world setting. Methods Medical records were eligible for adult patients with type 2 diabetes, on a basal bolus insulin regimen for 1 year or more, device use for 3 months or more before the start of the study, an HbA1c concentration up to 3 months prior to starting device use (patients were using blood glucose monitoring for self-management) between 64 and 108 mmol/mol (8.0–12.0%) plus an HbA1c determination 3–6 months after commencing flash glucose monitoring use. Results Records were analysed from 18 medical centres in Austria (n = 92), France (n = 88) and Germany (n = 183). Baseline HbA1c results, recorded up to 90 days before the start of device use, were comparable across the three countries and were reduced significantly by 9.6 ± 8.8 mmol/mol mean ± SD (Austria [0.9 ± 0.8%], p < 0.0001), 8.9 ± 12.5 mmol/mol (France [0.8% ± 1.1], p < 0.0001) and 10.1 ± 12.2 mmol/mol (Germany [0.9% ± 1.1], p < 0.0001). No significant differences were detected between age group, sex, BMI or duration of insulin use. Conclusions Three European real-world, chart review studies in people with type 2 diabetes managed using basal bolus insulin therapy each concluded that HbA1c was significantly reduced after changing to use of flash glucose monitoring for 3–6 months in a real-world setting.Keywords
Funding Information
- Abbott Diabetes Care
This publication has 19 references indexed in Scilit:
- Use of Flash Glucose-Sensing Technology for 12 months as a Replacement for Blood Glucose Monitoring in Insulin-treated Type 2 DiabetesDiabetes Therapy, 2017
- Flash Glucose-Sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-Treated Type 2 Diabetes: a Multicenter, Open-Label Randomized Controlled TrialDiabetes Therapy, 2016
- Sensor and software use for the glycaemic management of insulin-treated type 1 and type 2 diabetes patientsDiabetes & Vascular Disease Research, 2016
- The OPT2MISE Study – A Review of the Major Findings and Clinical ImplicationstouchREVIEWS in Endocrinology, 2015
- HbA1c and Risk of Severe Hypoglycemia in Type 2 DiabetesDiabetes Care, 2013
- Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality ratesJournal of Innovation in Health Informatics, 2011
- Risk factors and prevalence of diabetic peripheral neuropathy: A study of type 2 diabetic outpatients in BangladeshInternational Journal of Diabetes in Developing Countries, 2010
- Measuring inconsistency in meta-analysesBMJ, 2003
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.1998
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998